NSE: DCAL | BSE: 540701

Strong Performer, Under Radar

Download real time

236.70 0.35 (0.15%)

26.48% Fall from 52W High

109.3K NSE+BSE Volume

NSE 03 Dec, 2025 3:31 PM (IST)

3,711.1

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

Dishman Carbogen Amcis Ltd. share price target and research reports

Name: Latest research reports of Dishman Carbogen Amcis Ltd. authored by HDFC Securities and published by - Trendlyne research reports.
Item: Dishman Carbogen Amcis Ltd.
Rating: 5
Author: HDFC Securities

Latest analyst research reports with target prices and PDF download for DCAL, BSE:540701 Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd.

25 Jan 2019

236.70

0.15%

Dishman Carbogen Amcis (3QFY19): Several triggers for growth. Maintain BUY

Buy: Dishman Carbogen Amcis Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 380 (15x Dec-20E EPS). While Dishmans (DCAL) 3Q performance was ahead of our estimates, revenue growth was muted as a large chunk of orders was shifted over to 4Q. Despite revenue growth being limited to 4/7% YoY/QoQ, a shift in business mix towards high-margin segments (CRAMS India and Vit. D) led to a 750bps YoY expansion in gross margin (up to 85% in 3Q) and a 10% YoY growth in EBITDA (despite higher opex), with margin at 27.7% (+136bps YoY).

Number of FII/FPI investors increased from 71 to 78 in Sep 2025 qtr.

Dishman Carbogen Amcis Ltd.

25 Jan 2019

236.70

0.15%

BP Equities Dishman Carbogen Amcis Ltd Q3FY19 Res

Buy: Dishman Carbogen Amcis Ltd.

BP Wealth

Dishman Carbogen Amcis Ltd. is trading below all available SMAs

Dishman Carbogen Amcis Ltd.

07 Dec 2018

236.70

0.15%

Dishman Carbogen Amcis (Update): On the right track. Maintain BUY

Buy: Dishman Carbogen Amcis Ltd.

Target

HDFC Securities

We expect this to not only drive further growth and profitability, but also reduce dependence on single blockbusters (like Niraparib), leading to lower earnings risk. We re-iterate our positive stance on the company and maintain BUY with a TP of Rs 355 (15x Sep'20E EPS). One of DCALs US based clients is preparing to commercialize an antibiotic product in Feb-19. The product was approved by the US FDA in Oct-18 for the indication of community-acquired bacterial pneumonia (CABP) and acute bacterial skin infection (ABSSSI). This will be the third commercial launch from DCALs pipeline over FY18-19. We believe DCAL could generate annual revenue of US$ 4-5mn in the initial years.

Dishman Carbogen has lost -18.88% in the last 1 Month

Dishman Carbogen Amcis Ltd.

05 Nov 2018

236.70

0.15%

Dishman Carbogen Amcis (2QFY19): Mouth-watering valuations. Maintain BUY

Buy: Dishman Carbogen Amcis Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 350 (15x Sep-20E EPS). Dishman (DCAL) saw an in-line quarter with revenue at Rs 4.5bn (+1/-7% YoY/QoQ) driven by growth in the domestic business and Vitamin D segment. Gross margin expanded 250/740bps YoY/QoQ to 84.6% led by favorable forex and improved business mix. As a result, EBITDA margin jumped to 28.7% (up 368bps QoQ). PAT was at Rs 440mn, down 9% YoY, dragged by higher taxes, which includes Rs 70mn related to tax paid on subsidiary dividend.

Number of FII/FPI investors increased from 71 to 78 in Sep 2025 qtr.

Dishman Carbogen Amcis Ltd.

01 Oct 2018

236.70

0.15%

Dishman Carbogen Amcis (Annual Report Analysis): Multiple tailwinds ahead. Maintain BUY

Buy: Dishman Carbogen Amcis Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 415 (11x EV/EBITDA). DCALs FY18 annual report highlights its focus on cost optimization, improving business mix, commitment to reduce debt, strong hedging policies and reduced free cash flow due to higher capex in FY18. The revenue, EBITDA, and PAT largely remained flat in FY18 owing to fully utilized developmental capacity in Switzerland entity (~56% of revenues) and reduced supplies of old products like Eprosartan from India.

Dishman Carbogen Amcis Ltd. is trading below all available SMAs

Dishman Carbogen Amcis Ltd.

04 Sep 2018, 12:00AM

236.70

0.15%

Dishman Carbogen Amcis

IPO Note: Dishman Carbogen Amcis Ltd.

ICICI Securities Limited

Source: Capital Line, ICICI Direct Research; *FY15 and FY16 financials are for Dishman Pharma and Chemicals Ltd We met the management of Dishman Carbogen Amcis (Dishman) and also visited its key high potent (Hipo) oncology plant at Bavla, Gujarat, to gain an insight into the company's contract research & manufacturing (CRAMs) business. Incorporated in 1983, Dishman is a fully-integrated CRAMS player (76% of FY18 revenues) for new chemical entities (NCEs) molecules. It has a presence across the CRAMs value chain from process...

Number of FII/FPI investors increased from 71 to 78 in Sep 2025 qtr.

Dishman Carbogen Amcis Ltd.

27 Jul 2018

236.70

0.15%

Dishman Carbogen Amcis (1QFY19): Growth on track. Maintain BUY

Buy: Dishman Carbogen Amcis Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 440 (11x FY20E EV/EBITDA). DCAL delivered improved performance in 1QFY19 with revenue at Rs 4.8bn, up 42%YoY on a low base and up 7%QoQ. EBITDA margin recovered 400bps YoY to 25%, while dropping 200bps sequentially. The sequential drop was primarily owing to an increase in other expense and no reduction in employee cost. PAT at Rs 396mn was up 205%YoY owing to a low base, and down 22%QoQ due to decline in other income and higher interest cost.

Number of FII/FPI investors increased from 71 to 78 in Sep 2025 qtr.

Dishman Carbogen Amcis Ltd.

27 Jul 2018

236.70

0.15%

Result Review of Dishman Carbogen Amcis

Buy: Dishman Carbogen Amcis Ltd.

Recommendation Target

IDBI Capital

Dishman Carbogen Amcis's (Dishman) Q1FY19 revenue was a marginal miss but EBITDA/PAT were below our estimates by 31.9%/24.7%. Sales grew 32.6% YoY to Rs4.5 bn while EBITDA/PAT increased 26.7%/204.5% to Rs872/396 mn.EBITDA margins...

Dishman Carbogen Amcis Ltd. is trading below all available SMAs

Dishman Carbogen Amcis Ltd.

10 Jul 2018

236.70

0.15%

Pharmaceuticals: 1QFY19 Results Preview

Sector Update: Dishman Carbogen Amcis Ltd.

HDFC Securities

We believe FY19 may see a gradualcomebackfor large cap pharma companies, driven by (1) Actual and likely regulatory resolutions, (2) Moderating price erosion and (3) Several product launches across generic and specialty categories in 2HFY19. For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth (~13%) in revenues. EBITDA and PAT will grow at 25% and 28% YoY respectively. However, this growth is on the favorable base of 1QFY18, which was affected by GST disruption. Sequentially, revenues, EBITDA and PAT are likely to remain flat due to lack of lucrative approvals in the US and continued investment for specialty business. Within the sector, depreciated rupee is likely to benefit CRAMS companies like DIVIS and DCAL. Most of the US focused companies will report flat sequential growth and steady EBITDA margin